Eli Lilly And BI Japan Display Non-Inferiority Of Lantus Biosimilar In Phase III Trials
This article was originally published in PharmAsia News
Executive Summary
Eli Lilly Japan and Boehringer Ingelheim Japan have shown non-inferiority of the long-acting insulin analog Lantus (insulin glargine) biosimilar in international Phase III trials involving roughly 1,300 participants, the companies announced recently.